Goldman Sachs
GRTX

Goldman Sachs’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History

Goldman Sachs’s Portfolio GRTX Stock Details GRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-11,974
Closed -$2.1K – 5906
2023
Q3 		$2.1K Sell
11,974
-19,828
-62% -$24.6K ﹤0.01% 5479
2023
Q2 		$99.2K Buy
31,802
+20,487
+181% +$61K ﹤0.01% 5359
2023
Q1 		$29K Sell
11,315
-48
-0.4% -$99 ﹤0.01% 5625
2022
Q4 		$16.9K Sell
11,363
-92
-0.8% -$149 ﹤0.01% 5717
2022
Q3 		$20K Sell
11,455
-182
-2% -$257 ﹤0.01% 5940
2022
Q2 		$15K Sell
11,637
-4,201
-27% -$7.2K ﹤0.01% 6218
2022
Q1 		$38K Sell
15,838
-6,311
-28% -$16.4K ﹤0.01% 6316
2021
Q4 		$102K Buy
22,149
+10,428
+89% +$34.5K ﹤0.01% 6122
2021
Q3 		$95K Buy
11,721
+1
+0% +$9 ﹤0.01% 5925
2021
Q2 		$115K Sell
11,720
-1,085
-8% -$8.82K ﹤0.01% 5910
2021
Q1 		$113K Sell
12,805
-3,584
-22% -$39.3K ﹤0.01% 5809
2020
Q4 		$168K Sell
16,389
-4,717
-22% -$51.6K ﹤0.01% 5149
2020
Q3 		$191K Buy
+21,106
New +$167K ﹤0.01% 4934

Other funds holding GRTX

GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs's GRTX Position: Q4 2023 in Review

Goldman Sachs sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q4 2023, closing a stake of 11,974 shares — an estimated $2.1K sold.

Goldman Sachs first reported a position in GRTX in Q3 2020 and held it in 13 quarters. The position peaked at $191K in Q3 2020. 37 funds tracked by Wall St. Rank hold GRTX as of Q4 2023.

  • Goldman Sachs reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Goldman Sachs sold 11,974 Galera Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $2.1K.
  • Goldman Sachs first reported a position in Galera Therapeutics, Inc. Common Stock in Q3 2020 and held it in 13 quarters.
  • Goldman Sachs's Galera Therapeutics, Inc. Common Stock position peaked at $191K in Q3 2020.
  • 37 funds tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Goldman Sachs's 13F filing for Q4 2023, filed 13 Feb 2024.